Improved prognosis of diabetic nephropathy in type 1 diabetes

Kidney International

Volumn 87, Issue 2, 2015, Pages 417-426

  Andrésdóttir, Gudbjörg ^a   Jensen, Majken L ^a   Carstensen, Bendix ^a   Parving, Hans Henrik ^b,c,d   Hovind, Peter ^a   Hansen, Tine W ^a   Rossing, Peter ^a,c,d  

^a STENO DIABETES CENTER   (Denmark)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

diabetes mellitus; diabetic nephropathy; end stage renal disease; glomerular filtration rate; mortality; progression of chronic renal failure

Indexed keywords

CREATININE;

ADULT; ARTICLE; CAUSE OF DEATH; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLASMA CLEARANCE; PROGNOSIS; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL RATE; COHORT ANALYSIS; COMPLICATION; DENMARK; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE COURSE; EPIDEMIOLOGY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PATHOPHYSIOLOGY; TIME FACTOR;

ADULT; COHORT STUDIES; DENMARK; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; TIME FACTORS;

EID: 84922247841     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.206     Document Type: Article

References (46)

1. Andersen AR, Christiansen JS, Andersen JK et al. Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983; 25: 496-501.
2. Kussman MJ, Goldstein H, Gleason RE. The clinical course of diabetic nephropathy. JAMA 1976; 236: 1861-1863.
3. Groop PH, Thomas MC, Moran JL et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009; 58: 1651-1658.
4. Parving H-H, Mauer M, Fioretto P et al. Diabetic Nephropathy. in. edited by Taal MW et al. Brenner and Rector: The KIDNEY (vol 1), Elsevier: Philadelphia, USA, 2012, pp 1411-1454.
5. Parving HH, Andersen AR, Smidt UM et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 1: 1175-1179.
6. Mogensen CE. Long-Term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed) 1982; 285: 685-688.
7. Bjö rck S, Mulec H, Johnsen SA et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339-343.
8. Brenner BM, Cooper ME, de ZD et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
9. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
10. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
11. Hovind P, Rossing P, Tarnow L et al. Progression of diabetic nephropathy. Kidney Int 2001; 59: 702-709.
12. Astrup AS, Tarnow L, Rossing P et al. Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. Kidney Int 2005; 68: 1250-1257.
13. Parving HH, Hommel E. Prognosis in diabetic nephropathy. BMJ 1989; 299: 230-233.
14. Suissa S, Hutchinson T, Brophy JM et al. ACE-inhibitor use and the long-Term risk of renal failure in diabetes. Kidney Int 2006; 69: 913-919.
15. Rossing P, Parving H-H, de ZD. Renoprotection by blocking the RAAS in diabetic nephropathy-fact or fiction? Nephrol Dial Transplant 2006; 21: 2354-2357.
16. Forsblom C, Harjutsalo V, Thorn LM et al. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 2011; 22: 537-544.
17. Rosolowsky ET, Skupien J, Smiles AM et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol 2011; 22: 545-553.
18. Sorensen VR, Hansen PM, Heaf J et al. Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. Kidney Int 2006; 70: 187-191.
19. Danish Society of Nephrology, Danish Nephrology Registry Annual Report 2010. available from http://www.nephrology.dk/ Publikationer/Landsregister/%C3%85rsrapport%202010.pdf (accessed 3 May 2013), [in Danish].
20. The Danish National Diabetes Register 2007. Danish Health and Medicines Authority. Nye tal fra Sundhedsstyrelsen 2009; 13: 1-9[in Danish].
21. Williams ME. Diabetic CKD/ESRD 2010: a progress report? Semin Dial 2010; 23: 129-133.
22. Comas J, Arcos E, Castell C et al. Evolution of the incidence of chronic kidney disease Stage 5 requiring renal replacement therapy in the diabetic population of Catalonia. Nephrol Dial Transplant 2013; 28: 1191-1198.
23. Haapio M, Helve J, Groop PH et al. Survival of patients with type 1 diabetes receiving renal replacement therapy in 1980-2007. Diabetes Care 2010; 33: 1718-1723.
24. Krolewski AS, Bonventre JV. High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline. Semin Nephrol 2012; 32: 407-414.
25. DCCT/EDIC Research Groupde Boer IH, Sun W et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365: 2366-2376.
26. Retnakaran R, Cull CA, Thorne KI et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74. Diabetes 2006; 55: 1832-1839.
27. Rossing K, Christensen PK, Hovind P et al. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004; 66: 1596-1605.
28. de Boer IH, Rue TC, Cleary PA et al. Long-Term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: An analysis of the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Arch Intern Med 2011; 171: 412-420.
29. Keane WF, Brenner BM, de ZD et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003; 63: 1499-1507.
30. Breyer JA, Bain RP, Evans JK et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 1996; 50: 1651-1658.
31. Yokoyama H, Tomonaga O, Hirayama M et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 1997; 40: 405-411.
32. Bakris GL, Weir MR, Shanifar S et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003; 163: 1555-1565.
33. Gall MA, Borch-Johnsen K, Hougaard P et al. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995; 44: 1303-1309.
34. Orth SR, Ritz E. The renal risks of smoking: an update. Curr Opin Nephrol Hypertens 2002; 11: 483-488.
35. Baber U, Gutierrez OM, Levitan EB et al. Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers. Am Heart J 166: 373-380.
36. Moy CS, LaPorte RE, Dorman JS et al. Insulin-dependent diabetes mellitus mortality. The risk of cigarette smoking. Circulation 1990; 82: 37-43.
37. Hallan SI, Matsushita K, Sang Y et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA 2012; 308: 2349-2360.
38. Tonelli M, Muntner P, Lloyd A et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a populationlevel cohort study. Lancet 2012; 380: 807-814.
39. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169.
40. Levey AS, Gassman JJ, Hall PM et al. Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean. Modification of Diet in Renal Disease (MDRD) Study Group. J Am Soc Nephrol 1991; 1: 1087-1094.
41. Brochner-Mortensen J. A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 1972; 30: 271-274.
42. Christensen PK, Lund S, Parving HH. The impact of glycaemic control on autoregulation of glomerular filtration rate in patients with non-insulin dependent diabetes. Scand J Clin Lab Invest 2001; 61: 43-50.
43. Carrillo S. Updated Information for IDMS Traceable VITROS Chemistry Products CREA Slides,. Ortho Clinical Diagnostics: Rochester, NY, 2008 available from http://clincalc.com/Downloads/OrthoClinicalDiagnostics-IDMS-20080612.pdf (accessed 27 December 2013).
44. Carstensen B, Plummer M. Using Lexis objects for multi-state models in R. J Stat Softw 2011; 38: 1-18.
45. Plummer M, Carstensen B. Lexis: An R class for epidemiological studies with long-Term follow-up. J Stat Softw 2011; 38: 1-12.
46. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2011 available from http://www.r-project.org/ (accessed 1 October 2013).